Toxicity and pharmacokinetics of ciprofloxacin

A L Marchese1, V S Slana, E W Holmes

  • 1Department of Ophthalmology, Loyola University Medical Center, Maywood, Illinois.

Journal of Ocular Pharmacology
|January 1, 1993
PubMed

Insights

Intravitreal injections of ciprofloxacin showed potential ocular toxicity at higher doses (500 and 1000 micrograms) in rabbits, with no significant toxicity observed at 250 micrograms. This suggests a safe dose for potential intraocular infections.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Microbiology

Background:

  • Ciprofloxacin, a broad-spectrum fluoroquinolone antibiotic, achieves therapeutic levels in aqueous humor but limited intravitreal concentrations.
  • Previous research suggests intravitreal ciprofloxacin levels may be only marginally above the minimum inhibitory concentration (MIC90) for Gram-positive cocci.

Purpose of the Study:

  • To evaluate the ocular toxicity and pharmacokinetics of intravitreal ciprofloxacin in pigmented rabbits.
  • To determine a potentially safe and effective intravitreal dosage of ciprofloxacin for ocular infections.

Main Methods:

  • Intravitreal injections of varying ciprofloxacin doses (100, 250, 500, 1000 micrograms) were administered to rabbit eyes.
  • Electroretinograms (ERGs) and ophthalmoscopic examinations were performed to assess retinal function and toxicity.
  • Pharmacokinetic analysis was conducted after a single 250 microgram intravitreal injection.

Main Results:

  • Ophthalmoscopic examination revealed focal retinitis at 500 and 1000 microgram doses.
  • Significant reduction in ERG b-wave amplitude ratios was observed with the 1000 microgram dose.
  • No significant histological or ERG changes were noted at 100 or 250 microgram doses, with vitreous levels remaining detectable for up to 48 hours post-injection at 250 micrograms.

Conclusions:

  • Intravitreal ciprofloxacin at doses of 500 and 1000 micrograms demonstrates ocular toxicity in rabbits.
  • A dose of 250 micrograms of intravitreal ciprofloxacin appears safe and achieves therapeutic concentrations for at least 24 hours.
  • Further investigation into the 250 microgram dose is warranted for treating intraocular infections.

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...